Several studies have demonstrated the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients with solid tumors and non-Hodgkin lymphoma. In contrast, there is only sparse data on its prognostic role in patients with classical Hodgkin lymphoma (cHL). The aim of our study was to establish whether NLR could serve as an independent prognostic factor in a cohort of 990 patients with nodular sclerosis (NS)-cHL. After analysis of the log hazard ratio (HR) as a function of NLR, we chose the value 6 as cutoff. Patients with NLR >6 had a worse progression-free survival and overall survival compared to those with NLR ≤6; 84% vs 75% and 92% vs 88%, at 5 years, with an HR of 1.65 and 1.82, respectively. Multivariate analysis showed that the risk remained high with HR 1.44 and HR 1.54 in progression-free survival and overall survival, respectively. In summary, our study shows that NLR is a robust and independent prognostic parameter in NS-cHL, both in early and advanced disease. It is inexpensive and simple to apply.
| INTRODUCTION
There is an increasing amount of published data showing that tumor microenvironment, host immunity, and inflammatory responses all play an important role in determining the clinical course and outcome of patients with malignant lymphoma. Several investigators have considered the absolute lymphocyte count (ALC) 1 as an important biomarker of tumor infiltrating lymphocytes, reflecting host immunity status, while absolute monocyte count (AMC) 2 serves as a surrogate biomarker of tumor-associated macrophages within the tumor microenvironment, and the absolute neutrophil count (ANC) 3 as a measure of the systemic inflammatory response to malignancy. Inflammation is regarded as a critical component of tumor progression, and it is † Contributed equally.
evident that the tumor microenvironment, is largely coordinated by inflammatory cells, which play a central role in the neoplastic process, promoting, proliferation, survival, and migration of tumor cell via activation of signaling pathways. [4] [5] [6] Both AMC and ALC have been suggested as significant prognostic factors in Hodgkin lymphoma (HL), 1, 7 while the ANC and the neutrophil lymphocyte ratio (NLR) at diagnosis are both prognostic factors for survival in solid tumors 8 and recently have also been shown to have prognostic impact diffuse large B-cell lymphoma (DLBCL). 3, 9 In contrast, there is only sparse data on their role as prognostic factors in patients with HL. 10 In this regard different cutoff values have been established for NLR in DLBCL (3.5 or 4.0) 3, 9 and in HL (4.3). 10 In the present retrospective study the aim was to establish whether NLR could serve as a significant and independent prognostic factor, utilizing a large cohort of patients with nodular sclerosis (NS)-HL.
| PATIENTS AND METHODS

| Inclusion criteria
This is a retrospective study of previously untreated patients with NS-HL diagnosed according to the World Health Organization criteria. We 
| Outcomes
The primary end point of the study was to assess the impact of NLR on progression-free survival (PFS) and overall survival (OS).
| Statistical analysis
Progression-free survival was defined as the time from study entry to 
| Analysis of the cutoff
We have assessed the NLR by modeling it as continuous covariate in an explorative Cox PH restricted cubic spline regression. 15 The degrees of freedom for NLR were selected on the basis of the minimum Akaike information criterion. The cutoff value was chosen at the point where log(HR) = 0. Cutoff repeatability was checked with 1000 bootstrap replication sample.
| Importance of the covariate
We assessed the importance of NLR as predictor based on their bootstrap inclusion fractions, when 1000 replications were run in the Cox PH model. We used a hierarchical selection approach with log-likelihood ratio test with cutoff of 0.05, adding in Cox model the NLR covariate kept fixed the adjusting covariates age >45, male gender, hemoglobin (Hb) <10.5 g/dL, albumin <4 g/dL, staging IIb-IV, and AMC >750/uL. 16 In addition NLR was also studied as continuous variable. All statistical comparisons were 2 sides. The study design was retrospective. The simple size for this specific research was not planned. All analyses were performed with Stata SE/10 software.
3 | RESULTS
| Patient characteristics
The median age of the total of 990 patients enrolled in the study was (Table 1) . Patients received different combination chemotherapy regimens (Table 2) . After a median follow-up of 85 months (range 1-224 mo), 201 patients progressed or relapsed and 111 patients died from various causes. The estimated 5-year PFS and OS were 81% (95% CI, 78%-84%) and 91% (95% CI, 89%-93%), respectively. Of the 990 patients, 336 (34%) had NLR >6, and of these, 76% had stage IIB-IV and 37% had an IPS 3-7.
| Analysis of the cutoff
| Impact of the therapies
The patients with NLR ≤6 were treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) (49%) and bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)/(MEC)MOPP (25%), while the patients with NLR >6
were treated with ABVD (45%) and BEACOPP/(MEC)MOPP (40%), P < .001. Although the therapies in the 2 groups of patients with NLR ≤6 and NLR >6 were not well balanced, the log-rank test between the curves by therapies was not statistically significant for both PFS (P = .156) and for OS (P = .444) that showed that there was no impact of the treatments in the survival outcomes.
3.4 | Prognostic significance of NLR ratio
The PFS estimate for NLR ≤6 at 5 years was 84% (95% CI, 81%-87%) and 75% (95% CI, 70%-80%)for NLR >6. Comparison between the curves showed that this was statistically significant (P < .001, Figure 2A ). In univariate Cox PH regression analysis, NLR >6 showed a higher risk of disease progression with HR of 1.65 (95% CI, (7) 25 (9) 67 (7) Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone; CAD, lomustine, doxorubicin, and vindesine; CHT, chemotherapy; CR, complete response; EBV, epidoxorubicin, bleomycin, and vinblastine; EF, early failure; EVE, epirubicin, vinblastine and etoposide; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease; Stanford V, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone; VBM, vinblastine, bleomycin, and methotrexate.
Chi-square test for response by period of diagnosis, P = .328. Table 3 ). Multivariate analysis, after adjusting for age >45 years, male gender, Hb <10.5 g/dL, albumin <4/g/dL, stage IIB-IV (IPS factors), and AMC >750/uL, showed that the risk remained high with HR of 1.44 (Table 3) . Furthermore, in multivariate Cox PH regression analysis relating to NLR as a continuous parameter, the HR increased by 1.03 (95% CI, 1.01-1.04; P = .001) for any linear increase of one unit.
We also evaluated the prognostic effect of NLR ≤6 and >6 in patients with early (I-IIA) and advanced stage (IIB-IV); the log-rank test between the curves was statistically significant for both groups (P = .029 for early stage, and P = .033 for advanced stage patients, respectively, Figure 3a ,b).
| Overall survival
The OS for NLR ≤6 estimated at 5 years was 92% (95% CI, 90%-94%) and for NLR >6 was 88% (95% CI, 84%-92%). Comparison between the curves was statistically significant (P = .002, Figure 2B ). In univariate Cox PH regression analysis NLR >6 showed a higher risk of death with HR of 1.82 (Table 3b ). Multivariate analysis, after adjusting for age >45 years, male gender, Hb <10. We also evaluated the prognostic effect of the NLR ≤6 and >6 in groups of patients with early (I-IIA) as well as advanced stage (IIB-IV);
the log-rank test between the curves was statistically significant only for the advanced stage group (P = .036, Figure 3D ).
We also evaluated the prognostic role of ANC. As cutoff, determined with the same methodology used for NLR, we have found 
| DISCUSSION
The NLR is considered a simple and strong parameter for evaluating both inflammatory (neutrophils) and immune (lymphocyte) responses relating to prognosis in cancer patients. 8 In this regard, a number of studies have demonstrated the prognostic value of NLR at diagnosis and prior to therapy in patients with solid tumors. 8 In hematological malignancies, like DLBCL, high NLR 3, 7, [17] [18] [19] has also been associated with a poor prognosis and the results reported in our study on a different type of lymphoma-NS-HL are in line with these findings on DLBCL.
In HL, low ALC, 1 high AMC, 2 and low lymphocyte to monocyte After evaluation of all 312 patients, they concluded that NLR is an independent prognostic factor, which may help to stratify patients considered as low risk on the basis of the IPS. Here in our study we evaluated a much larger cohort of 990 patients with NS-HL and after extensive statistical analysis we chose 6.0 as the NLR cutoff value.
Overall, NS-HL patients with a NLR <6 had a and statistically significant better outcome in terms of both PFS and OS. In multivariate analysis the NLR remained an independent prognostic factor, along with other parameters like age >45, male gender, Hb <10.5 g/dL, albumin <4/g/dL, stage IIB-IV, and AMC >750/uL. Furthermore, unlike the IPS, NLR, at least regarding PFS, is a prognostic factor that is also applicable to patients with early stage disease. The reason for this correlation of NLR with poor prognosis is largely unknown. However, in this respect it has been reported that normal neutrophils are able to suppress T-cell function, while activated neutrophils have increased levels of arginase 1, which also cause T-cell suppression. 20 In addition to contributing to T-cell immune suppression, neutrophils may also exhibit tumor-promoting capabilities, like the induction of angiogenesis and enhancement of tumor spread by enhancing the expression of matrix metalloproteinase 9.
10
Indeed, one of the established "classical" IPS parameters in HL is peripheral blood leukocytosis, mainly because of an increased neutrophil count, and this has been validated extensively. 21 In our cohort, however, we would like to emphasize that there was no correlation between the absolute neutrophil number and prognosis. We have no ready explanation for this observation but it could theoretically be due to the fact that inflammation alone is insufficient to determine prognosis, and only when linked to decreased host immunity status, does it gain more powerful prognostic impact, as reflected by the impressive predictive value of NLR.
Our study has some obvious limitations that relate to the retrospective nature of the research design. On the other hand, its strength includes the large NS-HL sample size, long follow-up, and the accuracy of the cutoff determination based on a large cohort of cases.
In conclusion, here we show that NLR is a strong and independent prognostic parameter in NS-HL, inexpensive to perform, and simple to 
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